Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227

AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00.

In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of $0.52 on a GAAP basis, reflecting a decrease of 32.5%. Adjusted diluted EPS for the quarter reached $2.97, up 12.1%. Management reported that the results included an “unfavorable impact of $0.42 per share.”

Furthermore, AbbVie Inc. (NYSE:ABBV) delivered net revenues of $15.423 billion in fiscal Q2 2025, up 6.6% on a reported basis or 6.5% on an operational basis.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.